Cancer center may have found link between GIST, targeted therapy
ORLANDO, Fla. Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor patients respond to the targeted therapy Gleevec (imatinib mesylate). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.
“Imatinib has been the first drug that has really made a dent in GIST progression – up to 80% response – yet some GIST patients have little or no response to the drug,” commented Lori Rink, a postdoctoral fellow in the laboratory of Andrew Godwin at Fox Chase. “We are looking to see how we can help clinicians make better decisions in applying imatinib or additional therapies to their GIST patients,” she said. “Our data indicate that if we can alter the activity of some of these KRAB-zinc finger proteins, we may be able to enhance the effectiveness of imatinib therapy.”
Rink presented their findings at the 2009 Annual Meeting of the American Society of Clinical Oncology.
FMI postpones, reschedules annual events due to flu outbreak
ARLINGTON, Va. The Food Marketing Institute last week rescheduled its date for Future Connect in Dallas, which will now be held Oct. 12 to 14, and postponed its Marketechnics to the FMI 2010 event in Las Vegas.
“FMI appreciates the support and positive reinforcement we have received from the industry as we addressed the myriad issues resulting from the postponement of two events due to the influenza outbreak,” stated Leslie Sarasin, president, CEO of FMI. “We are thrilled to announce new plans to provide the industry with the essential education and insight provided by these events.”
Future Connect will now occur Oct.12 to 14 at the Hyatt Regency hotel in Dallas. All attendee registrations from the previously scheduled May dates for this event are automatically transferred to the October event. Companies may make substitutions on existing attendee registrations as needed.
Marketechnics is postponed and will be included in the FMI 2010 event in Las Vegas. Attendees of the postponed May 2009 event will receive a credit for attendance at FMI 2010 or any other FMI event valid through May 31, 2010. FMI 2010 is scheduled for May 10 to 13, 2010 at the Mandalay Bay Convention Center.
Study: Ginger reduces nausea associated with chemotherapy
ROCHESTER, N.Y. People with cancer can reduce post-chemotherapy nausea by as much as 40% by using ginger supplements, along with standard antivomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center.
About 70% of cancer patients who receive chemotherapy complain of nausea and vomiting.
“There are effective drugs to control vomiting, but the nausea is often worse because it lingers,” stated lead author Julie Ryan, assistant professor of dermatology and radiation oncology at Rochester’s James P. Wilmot Cancer Center. “Nausea is a major problem for people who undergo chemotherapy and it’s been a challenge for scientists and doctors to understand how to control it,” Ryan said.
The Phase II/III placebo-controlled, double-blind study included 644 cancer patients who would receive at least three chemotherapy treatments. They were divided into four arms that received placebos, 0.5 gram of ginger, 1 gram of ginger or 1.5 grams of ginger along with antiemetics (anti-vomiting drugs such as Zofran, Kytril, Novaban and Anzemet).
Patients took the ginger supplements three days prior to chemotherapy and three days following treatment. Patients reported nausea levels at various times of day during following their chemotherapy and those who took the lower doses had a 40% reduction.
Ginger is readily absorbed in the body and has long been considered a remedy for stomach aches. “By taking the ginger prior to chemotherapy treatment, the National Cancer Institute-funded study suggests its earlier absorption into the body may have anti-inflammatory properties,” Ryan said.
The research will be presented at the American Society of Clinical Oncology meeting in the Patient and Survivor Care Session on Saturday, May 30, in Orlando, Fla.